+1 Recommend
0 collections
      • Record: found
      • Abstract: not found
      • Article: not found

      A Randomized, Double-Blind, Placebo-Controlled Trial of Escitalopram in Patients with Asthma and Major Depressive Disorder

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          <div class="section"> <a class="named-anchor" id="S1"> <!-- named anchor --> </a> <h5 class="section-title" id="d4582120e203">Background</h5> <p id="P2">Depression is common in asthma and is associated with poor outcomes. However, antidepressant therapy in depressed asthma patients has been the topic of little research. </p> </div><div class="section"> <a class="named-anchor" id="S2"> <!-- named anchor --> </a> <h5 class="section-title" id="d4582120e208">Objective</h5> <p id="P3">This study examined the impact of antidepressant treatment with escitalopram vs. placebo on the Hamilton Rating Scale for Depression (HRSD), Inventory of Depressive Symptomatology-Self Report (IDS-SR), Asthma Control Questionnaire (ACQ), and oral corticosteroid use in asthma patients with major depressive disorder (MDD). </p> </div><div class="section"> <a class="named-anchor" id="S3"> <!-- named anchor --> </a> <h5 class="section-title" id="d4582120e213">Methods</h5> <p id="P4">Single site 12-week, randomized, double-blind, placebo-controlled, parallel-group trial of escitalopram (10 mg/d) was conducted in 139 outpatients with asthma and MDD. Randomization was stratified by oral corticosteroid use (≥ 3 bursts in past 12 months, yes or no) and baseline depressive symptom severity (HRSD ≥ 20) (higher severity, n=42) vs. &lt; 3 bursts, HRSD &lt; 20 or both (lower severity, n=97). The primary data analysis was conducted using HLM Version 7.01 on the higher and lower severity samples and <i>post hoc</i> was conducted on the combined sample. </p> </div><div class="section"> <a class="named-anchor" id="S4"> <!-- named anchor --> </a> <h5 class="section-title" id="d4582120e221">Results</h5> <p id="P5">Among the higher severity completers (n=21), a significant reduction in the ACQ (p=0.04) and oral corticosteroid use (p=0.04) was observed with escitalopram. In the combined sample, no significant differences were observed, but a trend toward greater reduction in the IDS-SR was observed with escitalopram (p=0.07). Side effects were comparable across groups. </p> </div><div class="section"> <a class="named-anchor" id="S5"> <!-- named anchor --> </a> <h5 class="section-title" id="d4582120e226">Conclusion</h5> <p id="P6">The findings suggest that patients with more severe asthma and depression symptomatology may have a positive response, in terms of both asthma and depressive symptom reduction, to antidepressant treatment. </p> </div>

          Related collections

          Author and article information

          The Journal of Allergy and Clinical Immunology: In Practice
          The Journal of Allergy and Clinical Immunology: In Practice
          Elsevier BV
          January 2018
          January 2018
          © 2018



          Comment on this article